This meeting aims to provide practical insights into some of
the recent improvements in this key area. There is a clear need
in drug development to reduce attrition from clinical studies
especially due to toxicology. Following on the success of the
'Designing Safer Medicines' meeting in 2011 we are planning a
one day follow-up meeting to review some of the progress in this
area. It was estimated that a 5-10% improvement in the attrition
rate could double the output of marketed drugs and various
preclinical approaches and strategies have been developed to
help the chemist design safer medicines.
the recent improvements in this key area. There is a clear need
in drug development to reduce attrition from clinical studies
especially due to toxicology. Following on the success of the
'Designing Safer Medicines' meeting in 2011 we are planning a
one day follow-up meeting to review some of the progress in this
area. It was estimated that a 5-10% improvement in the attrition
rate could double the output of marketed drugs and various
preclinical approaches and strategies have been developed to
help the chemist design safer medicines.
